PSMA-targeted therapy for non-prostate cancers

Area of Science:

• Oncology
• Nuclear Medicine
• Radiopharmaceutical Therapy

Background:

• Radioligand therapy (RLT) is vital for aggressive cancers like metastatic castrate-resistant prostate cancer (m-CRPC).
• Prostate-specific membrane antigen (PSMA)-targeted RLT is now FDA-approved for m-CRPC.
• PSMA expression in non-prostate tumors suggests potential therapeutic applications.

Purpose of the Study:

• To review the current clinical progress of PSMA-targeted RLT in non-prostate cancers.
• To highlight early findings and potential benefits in various malignancies.
• To identify areas for future research in PSMA RLT for new indications.

Main Methods:

• Literature review of clinical studies and case series involving PSMA RLT in non-prostate cancers.
• Analysis of reported efficacy, safety, and patient selection criteria.
• Identification of key research questions for advancing PSMA RLT in new cancer types.

Main Results:

• Early data from small cohorts suggest promise for PSMA RLT in salivary gland cancers, renal cell carcinoma, high-grade glioma, and soft tissue sarcoma.
• PSMA expression in tumor parenchyma and neovasculature is a key factor for targeting.
• Patient selection and understanding PSMA expression levels are critical for treatment success.

Conclusions:

• PSMA-targeted RLT is a promising therapeutic strategy for select non-prostate cancers.
• Further research is essential to optimize dosimetry, utilize PSMA PET/CT imaging as a biomarker, and establish safety and efficacy profiles.
• Identifying specific patient populations who will benefit most from PSMA RLT is crucial for clinical implementation.